Unichem Laboratories Q1FY13: Domestic growth a positive surprise
Key highlights of the result
- Domestic formulations steal the show in Q1FY13: Unichem reported 41% YoY growth (above Reliance Securities' estimates) led by export formulations (albeit on a low base, up 162.5% YoY) aided by rupee depreciation. Strong pick-up in domestic formulations (up 21% YoY) surprised positively post a struggle for last 5 quarters due to the ongoing shift in its distribution channel.
- Operating margin shows gradual improvement: Unichem recorded 430bp YoY increase in the operating margins at 17.6% (vis-à-vis Reliance Securities estimate of 17%) marking gradual improvement in the business over the past 5 quarters. Despite higher tax rates, Unichem reported a remarkable growth in its business performance, thereby, clinching 82.7% YoY growth to Rs27.5cr on an adjusted basis (against their estimate of Rs21cr). Including the forex gain of Rs5.6cr, the RPAT grew by 112.2% YoY to Rs33.1cr.
- Other Highlights: (1) Reliance Securities expected domestic formulations to resume normalcy in the far end of FY13E, thus a strong Q1FY13 is a positive surprise (2) Order commencement from Ghaziabad facility in November, 2011 continues to boost CRAMS growth; the facility contributes ~30% of the exports business (3) The management expects its Indore facility to commence operations in FY13E, thereby adding boost to its exports revenue (4) Niche Generics reported sales worth GBP2.3mn and net loss of GBP0.05mn during the quarter. However, the break-even is still some time away.
Outlook and Valuation
Unichem’s Q1FY13 results reflected gradual improvement in exports business and a swift turnaround in the domestic business. The strong growth in CRAMS on the export formulations front added cheer to the results. Better traction in the domestic formulations, increasing productivity gains and pay off from the investments done so far resulted in gradual improvement in the EBITDA margin.
The domestic business is the most profitable business of Unichem’s revenue pie. A positive trend in revenue growth, coupled with an operating leverage, thus is likely to have an accentuated impact on profitability. The full impact of CRAMS would also be visible from next year once the manufacturing facilities start operations at the optimal level.
Reliance Securities factors in the strong growth and revise their EPS for FY13E to Rs11.9 (v/s. Rs10.5 earlier) and for FY2014E to Rs14.2 (v/s. Rs12.4 earlier). Given the limited upside, Reliance Securities recommends Neutral on the stock with a fair value of Rs170.
Click here to read the full report
Reliance Securities comes from the house of Reliance Capital, one of India’s leading & prominent financial houses. Founded in 1986, Reliance Capital has come a long way from being into steady annuity yielding businesses such as leasing, bill discounting, and inter-corporate deposits to diversifying its activities in the areas of asset management and mutual fund; life and general insurance; consumer finance and industrial finance; stock broking; depository services; private equity and proprietary investments; exchanges, asset reconstruction; distribution of financial products and other activities in financial services.
For more information please write in to email@example.com
Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.
- Unichem Laboratories standalone Q1 net dips 16% at Rs 30.20 cr
- Unichem Labs: API business registers a robust growth of 80.6%, buy
- Unichem Labs: PAT expected to grow at a CAGR of 25% over 2012-2015E
- Unichem Laboratories: Net profit jumps to Rs310.34 mn
- Unichem Labs: Results in line, continued pressure on domestic formulations
Have a question?
Also On IndiaNotes.Com
- Eight personal finance tips if you just started earning
- Wallet stolen? Here's how you can get back on your feet
- Stock Recommendation: Accumulate D-Link with a target price of Rs195
- Cipla: Limited upside; Rating downgraded to neutral